Objective To analyze the efficacy and safety of transarterial chemoembolization combined with donafenib and tislelizumab in the treatment of mid-late stage liver cancer.Methods This was a single-center retrospective study,and involved patients with mid-late stage liver cancer who received TACE combined with donafenib and tislelizumab or TA-CE combined with donafenib at Shanghai Eastern Hepatobiliary Surgery Hospital from September 2021 to September 2022.Calculating the complete response rate(CR),partial response rate(PR),disease stability rate(SD),and disease progres-sion rate(PD)of the study population.The objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS),and the incidence of adverse reactions data of patients were collected and analyzed.The effectiveness and safety of the triple therapy regimen were comprehensively evaluated in both short-term and long-term durations.Results A total of 34 patients with mid-late stage liver cancer were enrolled.The median follow-up time was 12 months.In the overall study population,the complete response(CR)rate was 5 cases(14.7% ),partial response(PR)rate was13 cases(38.2% ),and stable disease(SD)rate was 10 cases(29.4% ).The overall ORR and DCR of mid-late stage liver cancer patients were 52.9% (95% CI:36.7% -68.6% )and 82.4% (95% CI:66.5% -91.7% ),respectively.The median PFS(mPFS)of all patients was10 months(95% CI:7.143-12.875),the median OS(mOS)was not reached,the 6-month overall survival rate was70.6% ,the12-month overall survival rate was61.8% ,and the18-month overall survival rate was 58.8% .Treatment-related adverse events(TRAEs)were reported in 30 cases(88.2% ),of which 7 cases(20.6% )were grade 3.No grade 4 or 5 TRAEs were reported.Conclusion The results of this study dem-onstrate that the combination of TACE with donafenib and tislelizumab exhibited encouraging efficacy and favorable safety profile in patients with mid-late stage liver cancer.
Transarterial chemoembolizationDonafenibTislelizumabMid-late stage liver cancer
NETL
NSTL
万方数据
